TTOO - T2 Biosystems highlights the benefits of T2MR technology vs. blood culture

Expert Review of Medical Devices, a peer-reviewed medical journal, has published meta-analysis findings confirming benefits of utilization of T2 Biosystems’ (TTOO) Magnetic Resonance (T2MR) technology for identification of bloodstream infections (BSIs) versus the current blood culture standard. Key meta-analysis results include:Significant reduction in the time to detection (MD=-81 hours) and time to species identification (MD=-77 hours) with T2MR vs. blood culture.Patients testing positive on T2MR received targeted antimicrobial therapy faster (MD=-42 hours); and patients testing negative were de-escalated from empirical therapy faster (MD=-7 hours) vs. blood culture.Length of ICU stay (MD=-5.0 days) and hospital stay (MD=-4.8 days) were shorter with T2MR vs. blood culture. The time-savings associated with T2MR technology provide meaningful clinical and economic value for patients and hospitals.“This analysis reinforces the clinical benefits of our technology compared to blood culture for BSI diagnosis and management,” said Aparna Ahuja MD, Chief Medical Officer.TTOO shares up 5.6% premarket trading at $1.50.

For further details see:

T2 Biosystems highlights the benefits of T2MR technology vs. blood culture